Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Canakinumab

Brand: Ilaris®
NICE TA: 302
Indication: Juvenile idiopathic arthritis (systemic) (NICE TA302)
Disease category: Musculoskeletal and joint disease
Commissioning responsibility: CCG
PbR excluded: Yes

Background

NICE is unable to make a recommendation about the use in the NHS of canakinumab for systemic juvenile idiopathic arthritis because no evidence submission was received from the manufacturer of the technology.

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  LMMG not recommended

Supporting documents:

NICE TA302 - Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) 

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black